Genmab — Oktober 2020

[Sukkeralf]

10:50 E L - ohh yes sorry !

[Bulder]

Thx E L

[Bulder]

I didn't realize we were that close to an amivantamab filing.

[Sukkeralf]

Its going to be fun to see milestones for filing and approval to get a feeling about how backloaded these Duobody deals are

[bongobob]

Meget informativt om Amivantamab. 6-12 md approval...moving to 1.line... Beklager hvis den har været linket. https://www.docwirenews.com/hematology-oncology/amivantamab-plus-lazertinib-combo-show-promising-results-at-esmo-2020/

[E_L]

SITC ID: 561
DuoBody-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13906&CONF=SITC20&ssoOverride=OFF&CKEY=

[GeorgeBest]

Thanks E L and bongobob

[E_L]

SITC ID: 412
First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13347&CONF=SITC20&ssoOverride=OFF&CKEY=

[GeorgeBest]

12:40 I like the phrase “superior”

[E_L]

Conclusions DuoBody-PD-L1×4-1BB demonstrated biologic activity and a manageable safety profile. Encouraging early clinical activity across different dose levels was observed in a heavily pretreated population with advanced solid tumors, including those resistant to prior immunotherapy or typically less sensitive to ICIs. Expansion cohorts of patients for whom DuoBody-PD-L1×4-1BB treatment could be relevant and biologically sound have started enrollment. Updated data will be presented.

[E_L]

Disease control, including stable disease at first assessment and partial responses in triple-negative breast cancer, ovarian cancer, and immune checkpoint inhibitor (ICI)–pretreated NSCLC, occurred in 40/61 patients (65.6%).

[E_L]

SITC ID: 704
Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody-CD3x5T4 in vitro and in vivo in solid cancer models https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13592&CONF=SITC20&ssoOverride=OFF&CKEY=

[Helge_LarsenPI-redaktør]

Opdaterede salgstal på Darzalex. https://www.proinvestor.com/boards/87573#87574

[E_L]

SITC ID: 617
Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13984&CONF=SITC20&ssoOverride=OFF&CKEY=

[E_L]

SITC ID: 621
A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13536&CONF=SITC20&ssoOverride=OFF&CKEY= (camidanlumab tesirine (ADCT-301))

[Plimsoller]

Tak Helge. Projekteret i den øveste del af intervallet. Hvis det ender sådan, så kan vi ikke klage

[Bulder]

Tak bongo. Så amivantamab 100% RR i første linje (få pts ganske vist) og godkendelse om et par år.

[bongobob]

Fantastiske nyheder både Amivantamab og PD-L1x4-1BB. Duobody validated

[E_L]

TEPEZZA (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)
10/14/20 https://ir.horizontherapeutics.com/news-releases/news-release-details/tepezzar-teprotumumab-trbw-data-phase-2-clinical-trial-evaluate

[E_L]

“These findings indicate this medication can provide relief at least a year after the last dose, including improvements in proptosis and diplopia, which are especially difficult symptoms to manage,”